Clinical Trial

VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICIs) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-22.
Trial Details
NCT Number NCT06337695
Lead Sponsor University of Calgary
Conditions Cancer, Cancer Metastatic
Enrollment 298 participants
Start Date 2024-07-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-04-02